Ma, L., Yang, B., Gu, S., Ren, T., Gao, D., Fang, J., Wu, J. (2025). Safety and efficacy of neoadjuvant disitamab vedotin in combination with pertuzumab with or without toripalimab for HER2-positive breast cancer: An open-label phase II trial.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.e12596